DEF: Revvity Sets 2026 Annual Meeting Agenda, Details 2025 Performance

Revvity, Inc. announces its 2026 annual meeting of shareholders, detailing 2025 financial performance, executive compensation, and corporate governance proposals including a reduced shareholder special meeting threshold.

Summary

• The 2026 annual meeting of shareholders for Revvity, Inc. will be held virtually on Tuesday, April 28, 2026, at 8:00 a.m. Eastern Time, with a record date of March 2, 2026.
• Key proposals for the meeting include the election of ten directors, ratification of Deloitte & Touche LLP as the independent registered public accounting firm, a non-binding advisory vote on executive compensation, and an amendment to the By-laws to allow shareholders owning 25% of stock to call a special meeting.
• A shareholder proposal regarding executive stock ownership will also be presented, which the board recommends voting AGAINST.
• For fiscal year 2025, GAAP revenue increased to $2,856 million from $2,755 million in 2024, and GAAP operating income from continuing operations rose to $357 million from $347 million.
• GAAP earnings per share from continuing operations decreased to $2.06 in 2025 from $2.30 in 2024, while Adjusted earnings per share from continuing operations increased to $5.06 in 2025 from $4.90 in 2024.
• The 2025 Global Incentive Compensation Program (Global ICP) achieved 124% of its target, reflecting strong short-term performance.
• The 2023 Long-Term Incentive Program (LTIP) PRSUs funded at 0% of target, as three-year average non-COVID organic growth (2%) and cumulative adjusted operating margin expansion (-130 basis points) fell significantly short of minimum goals (8% and 100 basis points, respectively).
• Revvity Health Sciences is facing a $1 billion lawsuit from marijuana testing laboratories alleging deceptive marketing and sales of ineffective cannabis testing equipment.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as presenting a mixed financial picture with some short-term outperformance against targets but a notable failure to meet long-term incentive goals. Positive corporate governance changes are balanced by ongoing market challenges and a significant lawsuit.

Positives

• Exceeded financial targets for fiscal year 2025 despite a dynamic market environment.
• Adjusted earnings per share from continuing operations increased to $5.06 in 2025 from $4.90 in 2024.
• GAAP revenue increased to $2,856 million in 2025 from $2,755 million in 2024.
• GAAP operating income from continuing operations increased to $357 million in 2025 from $347 million in 2024.
• The 2025 Global Incentive Compensation Program (Global ICP) achieved 124% of target, indicating strong short-term performance.
• Diagnostics segment revenue increased by 5%, driven by increased demand in immunodiagnostics and reproductive health businesses.
• Life Sciences segment revenue increased by 2%, led by growth in the Signals Software business.
• Achieved non-hazardous waste diversion goals three years ahead of plan.
• Obtained an AAA ESG rating from MSCI, their highest possible score.
• The board proposes to amend By-laws to allow shareholders owning 25% of stock to call a special meeting, enhancing shareholder rights.
• All executive officers and directors are in compliance with stock ownership guidelines.

Negatives

• GAAP earnings per share from continuing operations decreased to $2.06 in 2025 from $2.30 in 2024.
• GAAP operating profit margin from continuing operations slightly decreased to 12.5% in 2025 from 12.6% in 2024.
• The 2023 Long-Term Incentive Program (LTIP) PRSUs funded at 0% of target, indicating a failure to meet long-term financial goals.
• Three-year average non-COVID organic growth of 2% was significantly below the minimum goal of 8% for the 2023 LTIP.
• Cumulative adjusted operating margin expansion of negative 130 basis points was below the minimum goal of 100 basis points for the 2023 LTIP.
• Shareholder proposal highlights concerns about consistent pressure on operating margins, lower volumes of high-margin diagnostic tests, unfavorable product mix, and tariff impacts.
• The Diagnostics segment faced significant headwinds in China, with sales declining due to changes in hospital lab reimbursement policies (DRGs), leading to a meaningful pullback in the Immunodiagnostics business.
• The academic and government customer segment continued to show weakness, with revenue declining in the low single digits year over year.
• Analysts raised questions about Revvity's ability to maintain profitability while investing in growth.
• Revvity Health Sciences is facing a lawsuit seeking $1 billion in damages from marijuana testing laboratories for allegedly selling equipment not designed to test cannabis effectively.

Risks

• Operating in a dynamic market environment with evolving macro and regulatory conditions.
• Potential for unanticipated outcomes from strictly formulaic compensation programs if not balanced with discretion.
• Risks associated with a lower shareholder threshold for calling special meetings, including potential for single stockholder influence, short-term opportunism, frivolous meetings, and increased administrative/financial burdens.
• Cybersecurity and related information technology issues pose risks to operational performance.
• Impact of environmental and social issues on the Company (ESG risks).
• Litigation risks, specifically the $1 billion lawsuit from marijuana testing laboratories regarding cannabis testing equipment.
• Pressure on operating margins due to factors like lower volumes of high-margin diagnostic tests, unfavorable product mix, and tariff impacts.
• Headwinds in the China Diagnostics segment due to changes in hospital lab reimbursement policies (DRGs).
• Weakness in academic and government customer segments affecting revenue.
• Challenges in maintaining profitability while simultaneously investing in growth initiatives.

Future Outlook

The company aims to continue driving sustainable business practices and goals, with a commitment to submit emission reduction targets for SBTi approval during the first half of 2026. Management believes Revvity's product offerings, leading market positions, global scale, financial strength, and strong culture provide a foundation for continued long-term growth, margin expansion, and robust cash flow generation, as it continues to expand the boundaries of human potential through science.

Management Comments

• "We overcame a dynamic market environment throughout 2025, ultimately exceeding our financial targets provided at the beginning of the year." Prahlad R. Singh, PhD, President and CEO.
• "Our outperformance in the face of an evolving macro and regulatory environment is both a testament to the hard work of our incredible team and the result of the transformation that has taken place at our Company in recent years." Prahlad R. Singh, PhD, President and CEO.
• "Our people are the driving force behind our innovation, and empowering them inspires exceptional performance and personal growth." Prahlad R. Singh, PhD, President and CEO.
• "For us, investing in our team represents our dedication to cultivating a workplace where everyone can thrive, contribute meaningfully, and find fulfillment in their career journey." Prahlad R. Singh, PhD, President and CEO.
• "We believe that the combination of strong top-and bottom-line financial performance creates shareholder value growth that is sustainable over the long term."

Industry Context

StockSavvy.ai notes that Revvity operates in the highly competitive health science solutions, biotechnology, and diagnostics industries. The company's focus on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics aligns with broader industry trends towards precision medicine and data-driven healthcare. The challenges faced in China's Diagnostics segment due to changing reimbursement policies (DRGs) reflect a common regulatory risk for global healthcare companies, impacting market access and product mix. The weakness in academic and government segments also points to broader funding or procurement shifts in those sectors.

Comparison to Industry Standards

• Revvity's 2025 peer group for executive compensation includes Agilent Technologies, Inc., Bruker Corporation, Hologic, Inc., The Cooper Companies, Inc., Avantor, Inc., Catalent, Inc., Illumina, Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, QIAGEN N.V., Waters Corporation, Bio-Techne Corporation, Exact Sciences Corporation, and QuidelOrtho Corporation.
• At the time the peer group was approved in 2024, Revvity's revenue was at the 25th percentile of the peer group median revenue ($3,593 million), and its market capitalization was at the 45th percentile of the peer group median market capitalization ($15,327 million).
• The 2025 LTIP Relative TSR Comparator Group includes 31 companies, encompassing the executive compensation peer group plus additional healthcare sector companies.
• The 2023 LTIP PRSUs funded at 0% of target, with three-year average non-COVID organic growth of 2% (below 8% minimum) and cumulative adjusted operating margin expansion of -130bps (below 100bps minimum), indicates underperformance against internal long-term financial goals compared to the challenging yet attainable targets set.
• The proposed 25% threshold for shareholders to call a special meeting aligns with market practice, with approximately one-third of S&P 500 companies providing such a right at 25%, and two-thirds of Revvity's 2025 peer group (12 public companies) setting the threshold at or above 25%.

Management Changes

Corporate Governance

Legal Proceedings

• Revvity Health Sciences is facing a lawsuit from more than two dozen marijuana testing laboratories seeking $1 billion in damages.
• The suit accuses Revvity of a knowingly and intentionally deceptive marketing and sales campaign to sell equipment that was not designed to test cannabis effectively.

Related Party Transactions

• The nominating and corporate governance committee has adopted written policies and procedures for the review of any transaction, arrangement or relationship in which Revvity was or is to be a participant, and in which one of our executive officers, directors, director nominees or 5% stockholders (or their immediate family members), or any entity in which persons listed above, either individually or in the aggregate, has a greater than 10% ownership interest, has or will have a direct or indirect material interest. No specific related party transactions are disclosed in this filing, only the policy.

Stakeholder Impact

• Shareholders: Potential for enhanced rights through the proposed by-law amendment for special meetings; impact from mixed financial results (GAAP EPS down, Adjusted EPS up); potential for long-term value creation through strategic focus and incentive alignment; potential impact from the $1 billion lawsuit.
• Employees: Focus on nurturing talent, well-being, and engagement through diverse corporate and AI-powered programs; competitive compensation and benefits programs; potential for growth and professional development; impact of organizational streamlining and integration.
• Customers: Continued innovation and new product introductions (e.g., T1D, Xynthetica); potential impact from the lawsuit regarding cannabis testing equipment.
• Suppliers: Commitment to sustainable procurement policies.
• Creditors: Financial strength and robust cash flow generation.

Next Steps

• The 2026 Annual Meeting of Shareholders will be held on April 28, 2026, to vote on director elections, auditor ratification, executive compensation, By-laws amendment, and a shareholder proposal.
• Revvity is committed to submitting its emission reduction targets for Science Based Targets initiative (SBTi) approval during the first half of 2026.
• The company will continue to drive sustainable business practices and goals.
• Management and the compensation and benefits committee will review the voting results of the non-binding advisory vote on executive compensation.
• Shareholders may recommend director candidates for the 2027 annual meeting by submitting names and biographical information to the Nominating and Corporate Governance Committee.
• Shareholders may submit proposals for the 2027 annual meeting by November 16, 2026 (for inclusion in proxy) or by February 12, 2027 (for direct presentation).
• Proxy access nominations for the 2027 annual meeting must be received between November 29, 2026, and December 29, 2026.

Key Dates

Recommendation

While Revvity demonstrated resilience by exceeding short-term financial targets and achieving growth in key segments, the decline in GAAP EPS and the 0% funding of the 2023 Long-Term Incentive Program PRSUs signal challenges in achieving long-term strategic objectives. The ongoing $1 billion lawsuit and headwinds in the China Diagnostics market introduce significant uncertainties. The proposed corporate governance enhancements are positive, but the overall picture presents a mixed outlook, suggesting a "hold" recommendation as the company navigates these opportunities and challenges.

Keywords

Revvity, Proxy Statement, Annual Meeting, Executive Compensation, Corporate Governance, Financial Performance, GAAP, Adjusted EPS, Revenue, Operating Income, ESG, Shareholder Rights, Special Meeting, Stock Ownership, Deloitte & Touche, Biotechnology, Life Sciences, Diagnostics, Risk Management, Litigation, Capital Markets